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i.org/1burden, and a growing body of evidence suggests that nonehigh-density lipoprotein
cholesterol (non-HDL-C), triglycerides, and apolipoprotein B (apoB) are more accurate in
estimating lipid-related cardiovascular disease risk. Our objective was to compare the
relation among LDL-C, non-HDL-C, triglycerides, and apoB and the occurrence of future
vascular events and mortality in patients with manifest arterial disease. This is a pro-
spective cohort study of 7,216 patients with clinically manifest arterial disease in the Sec-
ondary Manifestations of Arterial Disease Study. Cox proportional hazard models were
used to quantify the risk of major cardiovascular events (MACE; i.e., stroke, myocardial
infarction, and vascular mortality) and all-cause mortality. Interaction was tested for type
of vascular disease at inclusion. MACE occurred in 1,185 subjects during a median follow-
up of 6.5 years (interquartile range 3.4 to 9.9 years). Adjusted hazard ratios (HRs) of
MACE per 1 SD higher were for LDL-C (HR 1.15, 95% conﬁdence interval [CI] 1.09 to
1.22), for non-HDL-C (HR 1.17, 95% CI 1.11 to 1.23), for log(triglycerides) (HR 1.12, 95%
CI 1.06 to 1.19), and for apoB HR (1.12, 95% CI 0.99 to 1.28). The relation among LDL-C,
non-HDL-C, and cardiovascular events was comparable in patients with cerebrovascular
disease, coronary artery disease, or polyvascular disease and absent in those with aneurysm
of abdominal aorta or peripheral artery disease. In conclusion, in patients with a history of
cerebrovascular, coronary artery, or polyvascular disease, but not aneurysm of abdominal
aorta or peripheral artery disease, higher levels of LDL-C and non-HDL-C are related to
increased risk of future MACE and of comparable magnitude.  2016 Elsevier Inc. All
rights reserved. (Am J Cardiol 2016;118:804e810)Several studies have made a direct comparison to assess
which lipid parameters has the strongest relation with risk of
vascular disease and overall; apolipoprotein B (apoB) and
nonehigh-density lipoprotein cholesterol (non-HDL-C)
appear to be favorable over low-density lipoprotein
cholesterol (LDL-C).1e5 Triglyceride-rich remnants are also
strongly related to cardiovascular events and triglycerides
and, therefore, could also be a good marker.6 Most stud-
ies1e5,7,8 comparing lipid parameters to cardiovascular
events were done in a primary prevention setting, whereas
patients at highest risk of cardiovascular events are those
with a history of clinically manifest arterial disease. Few
studies included patients with coronary heart disease, but
these studies were all randomized controlled trials with
statins.9,10 In these studies, non-HDL-C also had a strongerf aVascular Medicine, cVascular Surgery, dNeurology,
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0.1016/j.amjcard.2016.06.048association with risk of recurrent coronary or cerebral
ischemic events, although point estimates were lower for
recurrent compared with ﬁrst major cardiovascular events
(MACE). Because type of vascular disease (coronary, ce-
rebrovascular, and peripheral artery) inﬂuences the risk of
future vascular events,11 there is some evidence to assume
that type or extent of atherosclerosis can also inﬂuence the
relation between lipids and risk of a recurrent cardiovascular
disease. The aim of this study, therefore, was to evaluate and
compare the relation between LDL-C, non-HDL-C, tri-
glycerides, and apoB and the occurrence of future vascular
events and mortality, in patients with clinically manifest
arterial disease, and whether location of vascular disease
inﬂuences this relation.Methods
Data were used from patients enrolled in the Second
Manifestations of Arterial Disease (SMART) cohort. This is
a prospective, ongoing cohort study at the University
Medical Center Utrecht, The Netherlands, designed to study
the presence of concomitant arterial disease and risk factors
for atherosclerosis in a high-risk population. Patients, aged
18 to 80 years, newly referred to our institution with clini-
cally manifest arterial disease or with a vascular risk factor,www.ajconline.org
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and 2) were asked to participate. The study was approved by
the medical ethics committee of the University Medical
Center Utrecht, and informed consent was obtained from all
patients (n ¼ 10,645). A detailed description regarding
study rationale and design has been published before.12 The
present study used data from 7,216 patients enrolled from
September 1996 to March 2014 with either a history or a
recent diagnosis of manifest arterial disease. From 2005
onward, apoB was measured, and since 2006, apoB became
part of the standard screening protocol; therefore, ApoB
levels were available in 3,503 patients.
Clinically manifest atherosclerotic arterial disease was
deﬁned as cerebral, coronary, or peripheral artery disease or
aneurysm of the abdominal aorta. Cerebrovascular disease
included transient ischemic attack, cerebral infarction,
amaurosis fugax, retinal infarction, or a history of carotid
surgery. Coronary artery disease was deﬁned as angina
pectoris, myocardial infarction, cardiac arrest, or coronary
revascularization (coronary bypass surgical procedure or
coronary angioplasty). Patients with peripheral artery dis-
ease had symptomatic and documented obstruction of an
artery in a distal extremity and underwent surgical operation
(percutaneous transluminal angioplasty, bypass, or ampu-
tation). Abdominal aortic aneurysm (suprarenal or infrare-
nal) was deﬁned as a diameter of >3 cm or a history of
aortic aneurysm surgery. When patients had vascular disease
at multiple locations, they were deﬁned as having poly-
vascular disease. At inclusion, all patients completed a
health questionnaire and responded to questions including
history of vascular disease, hypertension, diabetes mellitus,
current medication use, and lifestyle. A physical examina-
tion took place where height, weight, and blood pressure
was measured. Blood samples were collected at baseline
after an overnight fast. Plasma total cholesterol, tri-
glycerides, and HDL-C were measured using commercial
enzymatic dry chemistry kits (Johnson & Johnson, New
Brunswick and Boehringer-Mannheim, Mannheim, Ger-
many, respectively). LDL-C was calculated using the Frie-
dewald formula13 up to a plasma triglycerides level of
9 mmol/L. This is in line with data showing that the Frie-
dewald formula can be used up to this level.14 In 32 patients,
plasma triglycerides levels were >9 mmol/L and LDL-C
could not be calculated. Non-HDL-C was calculated as to-
tal cholesterol minus HDL-C and apoB was measured on a
BNII nephelometer (Siemens, Erlangen, Germany).
Patients were biannually asked to ﬁll in a short question-
naire regarding hospitalization and outpatient clinic visits. If a
patient reported a possible event, all available relevant data
were collected, and the SMART Endpoint Committee that
consisted of 3 staff members independently classiﬁed all
events. Outcomes of interest for this study were occurrence of
stroke (ischemic and hemorrhagic, fatal, and nonfatal),
myocardial infarction (fatal and nonfatal), cardiovascular
mortality (fatal stroke, fatal myocardial infarction, death due
to terminal heart failure, ruptured abdominal aortic aneurysm,
and sudden death), MACE (composite of any of the previ-
ously listed outcomes), and all-cause mortality. Follow-up
duration was deﬁned as the period between study enrollment
and ﬁrst recurrent vascular event or death from any cause, date
to loss of follow-up, or the preselected date of March 2014.Baseline characteristics of the total study population are
presented for the total study population and stratiﬁed ac-
cording to the location of vascular disease. Single impu-
tation methods were used to account for missing data
(which was 2.2% for LDL-C, 0.7% for non-HDL-C, 0.6%
for triglycerides, alcohol, and smoking status, and 0.2% for
body mass index [BMI]). Because apoB was one of the
determinants and not missing at random, we choose not to
impute these values. If a patient had multiple events, the
ﬁrst recorded event was used in the analyses and patients
were censored if they were lost to follow-up. Cox pro-
portional hazard models were used to calculate hazard ra-
tios (HRs) and corresponding 95% conﬁdence intervals
(CIs) per lipid parameter for the occurrence of stroke,
myocardial infarction, cardiovascular mortality, MACE,
and all-cause mortality. Two models were used: model I
with adjustment for age and gender and model II with
adjustment for age, gender, BMI, smoking, alcohol, and
diabetes mellitus. Because triglycerides levels had a
skewed distribution, log transformation was applied, and to
be able to compare effect sizes of lipid parameters, HR
were calculated per 1 standard deviation (1 SD) increase in
LDL-C, non-HDL-C, log(triglycerides), and ApoB. A
sensitivity analysis took place with additional adjustment
for lipid-lowering therapy.
ApoB was not measured in the total population, and
therefore, analyses were repeated in a subset of patients
with complete lipid measurements (n ¼ 3,492). Effect
modiﬁcation on a multiplicative scale was tested by adding
an interaction term between “LDL-C/1 SD, non-HDL-C/1
SD, and log(triglycerides)/1 SD  type of vascular dis-
ease.” The models with and without the interaction term
were compared using the likelihood ratio test, and a p value
<0.05 was considered statistically signiﬁcant. If interaction
was present, analyses were stratiﬁed per type of vascular
disease (cerebrovascular disease, coronary artery disease,
abdominal aortic aneurysm, peripheral artery disease, or
polyvascular disease). This could not be done for apoB
because of a limited number of events in the subsets. Effect
modiﬁcation was also tested for diabetes mellitus, age 65
versus <65 years, number of beds with vascular disease,
categorized as 1, 2, or >2, year of inclusion, categorized
into 4 equal groups, and lipid parameters for risk of MACE.
Next, risk of vascular events and/or mortality was also
calculated per quartile of each of the lipid parameters, using
the lowest quartile as reference. The quartile ranges of
LDL-C were <2.12, 2.12 to 2.73, 2.74 to 3.53, and
>3.53 mmol/L, for non-HDL-C were <2.75, 2.75 to 3.48,
3.47 to 4.38, and >4.38 mmol/L, for triglycerides were
<1.00, 1.00 to 1.41, 1.40 to 2.00 mmol/L, and >2.00, and
for apoB, quartiles were divided into <0.68, 0.68 to 0.81,
0.82 to 0.99, and >0.99 g/dl. The proportional hazards
assumptions were veriﬁed using Schoenfeld residuals
plotted against (age adjusted) time scale. The open source
software program R 3.2.0 (R Development Core Team,
Vienna, Austria) was used for data analyses.
Results
The mean age at baseline was 60  10 years, and 74%
were men. Patients with coronary artery disease on average
Table 1













(n ¼ 7216) (n ¼ 1549) (n ¼ 3464) (n ¼ 265) (n ¼ 825) (n ¼ 1113)
Age (years) 60.1 (10.3) 58.1 (11.4) 60.0 (9.6) 65.0 (10.3) 57.6 (10.7) 63.5 (9.2)
Male sex 5319 (74%) 895 (58%) 2800 (81%) 226 (85%) 514 (62%) 884 (79%)
Current smoking 2300 (32%) 524 (34%) 799 (23%) 99 (37%) 499 (60%) 379 (34%)
Current alcohol use 793 (11%) 182 (12%) 332 (10%) 35 (13%) 71 (9%) 173 (16%)
Hypertension 6217 (86%) 1128 (73%) 3288 (95%) 208 (78%) 580 (70%) 1013 (91%)
Diabetes mellitus 1259 (17%) 203 (13%) 624 (18%) 33 (12%) 138 (17%) 261 (23%)
Cerebrovascular disease 2120 (29%) 1549 (100%) - - - 571 (51%)
Coronary Artery disease 4365 (60%) - 3464 (100%) - - 901 (81%)
Aneurysm of abdominal aorta 624 (9%) - - 265 (100%) - 359 (32%)
Peripheral vascular disease 1373 (19%) - - - 825 (100%) 548 (49%)
Blood pressure lowering agents 5315 (74%) 810 (52%) 3157 (91%) 138 (52%) 319 (39%) 891 (80%)
Statin therapy 4776 (66%) 823 (53%) 2794 (81%) 85 (32%) 306 (37%) 768 (69%)
Anti-platelet / anti-coagulant agents 5964 (83%) 1215 (78%) 3210 (93%) 105 (40%) 436 (53%) 998 (90%)
Body mass index (kg/m2) 26.8 (4.0) 26.4 (4.2) 27.3 (3.8) 26.0 (3.7) 26.0 (4.4) 26.9 (3.9)
Systolic blood pressure (mmHg) 140 (21) 142 (22) 137 (20) 144 (20) 145 (21) 144 (21)
Diastolic blood pressure (mmHg) 81 (11) 83 (12) 80 (11) 85 (12) 82 (11) 80 (12)
Total cholesterol (mmol/l) 4.86 (1.21) 5.00 (1.20) 4.58 (1.12) 5.41 (1.31) 5.56 (1.21) 4.91 (1.17)
Triglycerides (mmol/l) 1.4 (1.0 - 2.0) 1.3 (0.9 - 1.8) 1.4 (1.0 - 1.9) 1.4 (1.1 - 2.0) 1.5 (1.1 - 2.2) 1.6 (1.1 - 2.3)
High-density lipoprotein cholesterol (mmol/l) 1.23 (0.37) 1.34 (0.42) 1.19 (0.32) 1.22 (0.39) 1.28 (0.41) 1.17 (0.35)
Low-density lipoprotein cholesterol (mmol/l) 2.87 (1.04) 2.97 (1.07) 2.64 (0.93) 3.42 (1.16) 3.44 (1.10) 2.90 (1.03)
Non-high-density lipoprotein cholesterol (mmol/l) 3.63 (1.21) 3.65 (1.21) 3.39 (1.12) 4.20 (1.33) 4.29 (1.26) 3.74 (1.17)
Apolipoprotein B (g/dl)† 0.84 (0.24) 0.84 (0.27) 0.83 (0.23) 0.93 (0.27) 0.94 (0.26) 0.84 (0.23)
High-sensitivity C-reactive protein (mg/L) 2.0 (1.0 - 4.4) 1.8 (0.8 - 4.1) 1.6 (0.8 - 3.4) 3.7 (1.6 - 7.6) 3.2 (1.5 - 6.1) 2.9 (1.4 - 5.8)
All data are displayed as mean  SD, median (interquartile range) or n (%).
* Cerebrovascular disease was caused by hemorrhagic stroke in 17 of the 1549 patients.
† Apolipoprotein B measurements were available in a subset of n ¼ 3503 patients.
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likely to use blood pressureelowering medication, statins
and antiplatelet or anticoagulant therapy, and had a higher
BMI compared with the total study population. Patients with
peripheral artery disease more often were current smokers.
In 87% of the patients with polyvascular disease, vascular
disease was present in 2 vascular beds and 12% had vascular
disease in 3 locations. Patients with abdominal aortic
aneurysm and polyvascular disease were on average older at
baseline and those with polyvascular disease were more
likely to be diagnosed with diabetes and those with pe-
ripheral artery disease or abdominal aortic aneurysm had on
average higher total cholesterol, LDL-C, non-HDL-C, and
apoB levels (Table 1).
During a median follow-up of 6.5 years (IQR 3.4 to
9.9 years), 1,324 patients (18%) died (of whom 692 from a
vascular cause); 330 patients (5%) had a stroke, 435 patients
(6%) had a myocardial infarction, and 1,185 patients (16%)
had the composite outcome, MACE. After adjustment for
confounding, 1 SD higher LDL-C, non-HDL-C, tri-
glycerides, and apoB were related with higher risk of
MACE (HR 1.15, 95% CI 1.09 to 1.22 for LDL-C; HR 1.17,
95% CI 1.11 to 1.23 for non-HDL-C; HR 1.12, 95% CI 1.06
to 1.19 for log(triglycerides); and HR 1.12, 95% CI 0.99 to
1.27 for apoB) and also with increased risk of all-cause
mortality, as presented in Figure 1 (and in Supplementary
Table 1, which can be found online only). Although CIs
of apoB were wide, the risk of myocardial infarction was
23% higher per 1 SD higher apoB. In the sensitivity analysiswith additional adjustment for lipid-lowering therapy, the
effect estimates did not change, nor did additional adjust-
ment for hypertension, use of antiplatelet/anticoagulant
agents, and hs-CRP. Because apoB was measured from
2005 onward, we repeated the analyses in a subset of pa-
tients (n ¼ 3,492) with complete lipid measurements
(baseline characteristics are provided in Supplementary
Table 2, which can be found online only). Point estimates
for risk of vascular events and mortality for LDL-C, non-
HDL-C, and apoB in the subset were comparable with the
total study population (Supplementary Figure 1 and in
Supplementary Table 1, which can be found online only).
The relation between log(triglycerides) and cardiovascular
endpoints, however, was less evident in the subset of pa-
tients with complete lipid measurements.
The relation between levels of triglycerides and risk of
MACE was dependent of location of vascular disease at
inclusion (p value ¼ 0.04 for interaction between
log(triglycerides)  type of vascular disease). For LDL-C
and non-HDL-C, interaction was not statistically signiﬁ-
cant (p values 0.66 and 0.58, respectively). Results stratiﬁed
according to the type of vascular disease at baseline are
presented in Table 2. After adjustment for confounding, 1
SD higher LDL-C and non-HDL-C were related to an
increased risk of MACE in patients with a history of cere-
brovascular disease, coronary artery disease, or polyvascular
disease. The effect of 1 SD higher triglycerides on risk of
MACE was comparable magnitude in patients with cere-
brovascular disease or coronary artery disease but
Figure 1. The relation between lipid measurements and cardiovascular events and mortality. Presented data are HRs with 95% CI, adjusted for age, gender,
BMI, smoking, alcohol, and diabetes mellitus. 1 SD of LDL-C ¼ 1.05 mmol/L, non-HDL-C ¼ 1.21 mmol/L, log(TG) ¼ 0.53 mmol/L; in the total study
population of n ¼ 7,216 and 1 SD of apoB ¼ 0.24 g/L, measured in n ¼ 3,503 patients. * ApoB measurements were available in a subset 3,503 patients. Exact
HRs are presented in Supplementary Table 1.
Table 2
The relation between low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, log transformed triglycerides per 1 standard deviation and
risk of major cardiovascular events stratiﬁed for location of vascular disease
Subset Size (n ¼ ) Events (n ¼ ) LDL-C/1 SD Non-HDL-D/1 SD Log(TG)/1 SD*
HR (95% CI) HR (95% CI) HR (95% CI)
Cerebrovascular disease 1549 216 1.16 (1.01 - 1.33) 1.20 (1.05 - 1.37) 1.15 (1.00 - 1.32)
Coronary artery disease 3455 410 1.14 (1.04 - 1.25) 1.14 (1.05 - 1.23) 1.10 (1.00 - 1.22)
Peripheral artery disease 825 134 1.00 (0.84 - 1.20) 1.07 (0.90 - 1.28) 1.12 (0.94 - 1.33)
Aneurysm of abdominal aorta 265 74 1.10 (0.85 - 1.44) 1.07 (0.82 - 1.39) 0.92 (0.70 - 1.20)
Polyvascular disease 1113 344 1.13 (1.02 - 1.26) 1.12 (1.00 - 1.25) 1.06 (0.95 - 1.19)
Presented data are Hazard ratio with 95% conﬁdence intervals (HR (95% CI)), adjusted for age, sex, BMI, smoking, alcohol and diabetes mellitus.
LDL-C ¼ low-density lipoprotein-cholesterol; log(TG) ¼ log-transformed triglycerides; MACE ¼ major cardiovascular events; MI ¼ myocardial infarction;
non-HDL-C ¼ non-high-density lipoprotein-cholesterol.
* P value of 0.04 for interaction between log(TG)/1 standard deviation and type of vascular disease.
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with a history of peripheral artery disease or abdominal
aortic aneurysm, no association was present between lipid
parameters and risk of MACE. No interaction was present
between diabetes mellitus and LDL-C (p value 0.88), non-
HDL-C (p value 0.58), log(triglycerides) (p value 0.85), or
apoB (p value 0.83) and the risk of future MACE. Interac-
tion was also absent for age 65 versus <65 years (p values
were 0.07, 0.11, 0.99, and 0.81, respectively), for number of
beds with vascular disease (p values 0.31, 0.92, 0.10, and
0.52, respectively), and for year of inclusion (p value 0.08,
0.15, 0.90, and 0.38, respectively)  lipid parameters on
risk of MACE.
The risk of cardiovascular mortality, MACE, and all-
cause mortality was higher across quartiles of LDL-C,
non-HDL-C, and triglycerides (Figure 2). Patients in the
top quartile of non-HDL-C had an HR of 2.09 (95% CI 1.62
to 2.69) compared with the lowest quartile for risk of
vascular mortality, HR 1.60 (95% CI 1.34 to 1.91) for risk
of future MACE, and HR 1.54 (95% CI 1.29 to 1.83) for
risk of all-cause mortality. The relation between LDL-C or
triglycerides and future MACE were less strong; HR for
LDL-C was 1.47 (95% CI 1.24 to 1.75) and for triglycerides
1.32 (95% CI 1.11 to 1.57) and were also lower for risk of
all-cause mortality; HR for LDL-C was 1.38 (95% CI 1.16
to 1.63) and for triglycerides was 1.19 (95% CI 1.00 to
1.40). Patients in the top quartile of LDL-C (>3.53 mmol/L)had the highest risk for future stroke (HR of 1.88; 95% CI
1.33 to 2.64) compared with those in the lowest quartile
(LDL-C <2.12 mmol/L). Risk of future myocardial infarc-
tion was highest for patients in the top quartile of tri-
glycerides (>2.00 mmol/L) with an HR of 1.63 (95% CI
1.20 to 2.21) and for patients in the top quartile of non-
HDL-C (HR 1.55; 95% CI 1.15 to 2.08). None of the
apoB quartiles were associated with any of the end points
compared with the lowest quartile.
Discussion
In this study with patients from a secondary prevention
cohort, higher levels of LDL-C and non-HDL-C, tri-
glycerides, and apoB are related to increased risk of future
MACE. However, after stratiﬁcation for type of vascular
disease, the relation between higher levels of LDL-C and
non-HDL-C and risk of MACE are only present in patients
with cerebrovascular, coronary artery, or polyvascular
disease and absent in patients with abdominal aortic
aneurysm or peripheral artery disease. Higher levels of
triglycerides were also related to increased risk of MACE
in patients with cerebrovascular disease or coronary artery
disease.
The results of this present study are in line with a meta-
analysis of individual patient data from randomized
controlled trials with statin therapy,10 where in 24,053
Figure 2. Risk of vascular events and mortality, according to quartiles of LDL-C, noneHDL-C, log-transformed triglycerides, and apoB, using the lowest
quartile as reference. Presented data are HRs with 95% conﬁdence interval of lipid quartiles, using the lowest quartile as reference, for risk of stroke (A),
myocardial infarction (B), MACEs (C), vascular mortality (D), and all-cause mortality (E). HRs are adjusted for age, gender, BMI, smoking, alcohol, and
diabetes mellitus. The range of LDL-C quartiles were <2.12, 2.12 to 2.73, 2.74 to 3.53, and >3.53 mmol/L, the range of non-HDL-C quartiles were <2.75,
2.75 to 3.47, 3.48 to 4.38, and >4.38 mmol/L, for TG quartiles, the range was <1.00, 1.00 to 1.40, 1.41 to 2.00, and >2.00 mmol/L; and for apoB, quartiles
were divided into <0.68, 0.68 to 0.81, 0.82 to 0.99, and >0.99 g/dl. * ApoB measurements were available in a subset of 3,503 patients.
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MACE per 1 SD higher LDL-C, non-HDL-C, and apoB were
found. However, there are also studies showing that non-
HDL-C and/or apoB are more strongly related to cardiovas-
cular events than LDL-C.5,15,16 A possible explanation could
be a difference in endpoint because most studies focused on
coronary heart disease as an endpoint instead of MACE that
also includes nonfatal stroke.1,3e5 In our study, apoB was not
associated with an increased risk MACE. A possible expla-
nation could be that the patients in whom apoBwas measuredwere more recently included and, therefore, probably
received better (preventative) care. Statins, for instance, were
prescribed more often and LDL-C levels were lower in these
patients compared with the total study population. Interest-
ingly, apoB was stronger related with the risk of myocardial
infarction, compared with LDL-C, non-HDL-C, and tri-
glycerides. A possible explanation could be that because
apoB has a stronger associationwith inﬂammation and insulin
resistance17 and because inﬂammation plays an important role
in the pathogenesis of myocardial infarction, apoB has a
Preventive Cardiology/Lipids and Risk of Cardiovascular Disease 809stronger association with risk of myocardial infarction than
the other lipid parameters.
Another explanation for the difference in ﬁndings could
be differences in study populations. Most observational
studies that compare lipids included patients free of car-
diovascular disease at baseline,1e5 whereas the present
study population consisted of patients with a variety of
atherosclerotic disease. We hypothesized that type of
vascular disease would inﬂuence the association between
lipids and risk of recurrent events and that in patients with
extensive atherosclerosis, that is, multiple arterial events, the
risk attributable to lipids would be low or even negligible
because these patients already have a very high absolute risk
of MACE. Supporting this hypothesis is a recent study
regarding the association between type 2 diabetes and risk of
recurrent MACE, which showed that type 2 diabetes was no
longer a risk factor for recurrent MACE in patients with
vascular disease at multiple locations.18 In our study, we
found that point estimates for the association between non-
HDL-C, less so for LDL-C and risk of MACE, were lower
in patients with polyvascular disease than in the total study
population, thus not supporting our hypothesis. The risk of
recurrent MACE per 1 SD higher LDL-C, non-HDL-C, and
triglycerides was comparable in patients with a history of
cerebrovascular disease or coronary artery disease to the
total study population. In patients with a history of
abdominal aortic aneurysm or peripheral artery disease, no
association was found between lipids and vascular risk and
an explanation could be limited power or the difference in
risk factor proﬁle. Possibly other risk factors than lipids,
such as smoking, high blood pressure, and age drive risk of
recurrent MACE in patients with abdominal aortic aneurysm
or peripheral artery disease and adjusting for smoking, age,
and other factors attenuated the relation between lipids and
recurrent vascular events.
Compared with LDL-C, non-HDL-C, triglycerides, or
apoB overall did not performed vastly better in estimating
risk of recurrent events in our study. Although the body of
evidence is growing in favor of apoB and non-HDL-C,
using LDL-C as the main lipid parameter in clinical prac-
tice appears justiﬁable in patients with atherosclerotic dis-
ease. Measurement of triglycerides, non-HDL-C, and apoB,
however, remains important, especially in diagnosing spe-
ciﬁc dyslipidemias, such as familial hypercholesteremia and
dysbetalipoproteinemia, because these patients and their
families are at even higher risk of cardiovascular events.19
The strengths of this study are the prospective design and
relatively large sample size. The SMART cohort is a
contemporary hospital-based cohort with low loss to follow-
up (6%) and a large number of clinical events. To appreciate
the ﬁndings, limitations also need to be addressed. First, our
cohort represents a West European population with pre-
dominately Caucasians, which may not be representative of
other geographical locations. Second, measurement of apoB
became part of the standard baseline screening in 2006 and,
therefore, was available in 49% of the total study popula-
tion. Although CIs were wide, point estimates were
consistent in patients with complete lipid measurements and
because of the recent date of inclusion, perhaps give a better
reﬂection of the present clinical situation. Because of a
limited number of events, however, stratiﬁcation for type ofvascular disease at inclusion was not possible in the analyses
with apoB. Third, LDL-C was not measured directly but
calculated using the Friedewald formula, up to a serum
triglycerides level of 9 mmol/L, instead of the usual
4.5 mmol/L. Previous studies have found a linear relation
and high correlation between fasting direct measurement of
LDL-C and calculated LDL-C using the Friedewald for-
mula. In our study population, 3% of the patients had a
triglycerides >4.5 mmol/L. In these patients, LDL-C values
calculated with the Friedewald formula might be under-
estimated, which could have led to an underestimation in the
relation between LDL-C per 1 SD and risk of MACE.
A fourth limitation is that plasma lipid levels and data
regarding possible confounders, such as lipid-lowering
therapy, were only present at baseline. Although a sensi-
tivity analysis with additional adjustment of lipid-lowering
therapy did not change the results, risk of bias due to
preferential use of statins in high-risk subjects as showed
recently by Colantonio et al20 is still present. Besides, since
the start of the study in 1996 and present day, secondary
prevention and treatment options for cardiovascular events
have changed and also might have inﬂuenced the associa-
tion between lipids and cardiovascular disease risk. Inter-
action between year of inclusion  lipid parameters and risk
of cardiovascular events, however, was not present.
In this study, higher levels of LDL-C and non-HDL-C
are related to an increased risk of MACE in patients with
cerebrovascular, coronary artery, or polyvascular disease
and absent in patients with abdominal aortic aneurysm or
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